{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:31:50Z","timestamp":1790195510796,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ijcard.2016.11.181","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T07:34:34Z","timestamp":1478676874000},"page":"352-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["Cardiovascular outcomes with sodium\u2013glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials"],"prefix":"10.1016","volume":"228","author":[{"given":"Marwan","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed N.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam Y.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abuzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr F.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram Y.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Al-Ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amgad","family":"Mentias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez","family":"Nairooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony A.","family":"Bavry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijcard.2016.11.181_bb0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1871525714666151106121215","article-title":"A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin","volume":"13","author":"Syed","year":"2015","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"12","key":"10.1016\/j.ijcard.2016.11.181_bb0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.ijcard.2016.11.181_bb0015","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ijcard.2016.11.181_bb0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tips.2010.11.011","article-title":"Renal glucose reabsorption inhibitors to treat diabetes","volume":"32","author":"Bailey","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.ijcard.2016.11.181_bb0025","first-page":"243","article-title":"Update on SGLT2 inhibitor warning","volume":"315","author":"Voelker","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ijcard.2016.11.181_bb0030","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2016.11.181_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med."},{"issue":"12","key":"10.1016\/j.ijcard.2016.11.181_bb0040","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int. J. Clin. Pract."},{"issue":"22","key":"10.1016\/j.ijcard.2016.11.181_bb0045","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.11.181_bb0050","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.ijcard.2016.11.181_bb0055","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jdiacomp.2015.07.011","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years","volume":"29","author":"Liu","year":"2015","journal-title":"J. Diabetes Complicat."},{"issue":"11","key":"10.1016\/j.ijcard.2016.11.181_bb0060","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00228-015-1923-y","article-title":"Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis","volume":"71","author":"Yang","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijcard.2016.11.181_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004619","article-title":"The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials","volume":"4","author":"Sun","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijcard.2016.11.181_bb0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1472-6823-13-58","article-title":"Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials","volume":"13","author":"Berhan","year":"2013","journal-title":"BMC Endocr. Disord."},{"issue":"5","key":"10.1016\/j.ijcard.2016.11.181_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.ijcard.2016.11.181_bb0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7303","key":"10.1016\/j.ijcard.2016.11.181_bb0085","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.11.181_bb0090","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"9.4.4.2. Peto odds ratio method","author":"O'Connor","year":"2011"},{"key":"10.1016\/j.ijcard.2016.11.181_bb0095","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]","author":"Higgins","year":"2011"},{"issue":"3","key":"10.1016\/j.ijcard.2016.11.181_bb0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"7414","key":"10.1016\/j.ijcard.2016.11.181_bb0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.ijcard.2016.11.181_bb0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2016.11.181_bb0115","unstructured":"Effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02383238. Last accessed 2016."},{"issue":"19","key":"10.1016\/j.ijcard.2016.11.181_bb0120","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2016.11.181_bb0125","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ijcard.2016.11.181_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - the \u201cdiuretic hypothesis\u201d","volume":"30","author":"McMurray","year":"2015","journal-title":"J. Diabetes Complicat."},{"issue":"8","key":"10.1016\/j.ijcard.2016.11.181_bb0135","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus","volume":"37","author":"Kovacs","year":"2015","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.ijcard.2016.11.181_bb0140","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ijcard.2016.11.181_bb0145","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2016.11.181_bb0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"issue":"11","key":"10.1016\/j.ijcard.2016.11.181_bb0155","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.2337\/dc13-0506","article-title":"Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio deJaneiro Type 2 Diabetes Cohort Study","volume":"36","author":"Cardoso","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ijcard.2016.11.181_bb0160","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/eurheartj\/ehp507","article-title":"Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative","volume":"31","author":"Ronco","year":"2010","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2016.11.181_bb0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"EMPA-REG OUTCOME investigators. empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2016.11.181_bb0170","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.athoracsur.2015.09.070","article-title":"Perioperative statin therapy for patients undergoing coronary artery bypass grafting","volume":"101","author":"Barakat","year":"2016","journal-title":"Ann. Thorac. Surg."},{"issue":"11","key":"10.1016\/j.ijcard.2016.11.181_bb0175","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.amjcard.2015.02.053","article-title":"A. Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting","volume":"115","author":"Elgendy","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.11.181_bb0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2016.11.181_bb0190","unstructured":"Safety alerts for human medical products - canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR): drug safety communication - strengthened kidney warnings. Available at http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm506554.htm. Accessed July 16, 2016."},{"key":"10.1016\/j.ijcard.2016.11.181_bb0195","unstructured":"Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01730534. Accessed July 20, 2016."},{"key":"10.1016\/j.ijcard.2016.11.181_bb0200","unstructured":"Safety and effectiveness of SGLT-2 inhibitors in patients with heart failure and diabetes. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02397421. Accessed July 20, 2016."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316336580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316336580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:36:41Z","timestamp":1759091801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316336580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":39,"alternative-id":["S0167527316336580"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.181","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular outcomes with sodium\u2013glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}